OPRX News | Roxom Stocks

1 BTC

- USD

Loading market data...

Volume

96.56K

Next Earnings

November 5th

Mkt Cap

$156.2M

Volume

96.56K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?The Trade Desk (TTD) is strengthening its healthcare advertising position through a new integration with OptimizeRx (OPRX), giving advertisers access to authenticated healthcare professional inventory across 400+ EHR systems reaching ~800,000 verified HCPs. The inventory will be available via TTD's OpenPath platform in Q4 2026. This partnership complements TTD's recent expansions with Veeva Crossix and IQVIA Digital, potentially attracting more pharma and life sciences advertisers. However, TTD shares have declined 71.9% over the past year and carry a Zacks Rank #4 (Sell) rating.Zacks Investment Research · Sep 23, 2026

OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ETOptimizeRx Corp. (Nasdaq: OPRX) announced it will hold a conference call on August 12, 2026, at 4:30 p.m. ET to discuss its second quarter 2026 financial results ended June 30, 2026. The call will include management remarks followed by a Q&A session, with details and webcast access provided for investors.GlobeNewswire Inc. · Jul 29, 2026

OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing OfficerOptimizeRx Corp. announced the appointment of Sarah Bast as Chief Marketing Officer. Bast brings over 20 years of pharmaceutical marketing experience from roles at Publicis Health Media and major life sciences companies including Lilly, Bayer, Johnson & Johnson, and AstraZeneca. She will lead OptimizeRx's marketing strategy and go-to-market initiatives as the company expands its point-of-care technology solutions.GlobeNewswire Inc. · Jul 23, 2026

OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning PlatformsOptimizeRx announced the launch of its patent-pending Natural Language Audience Builder (NLAB), an AI-powered tool designed to be embedded in demand-side platforms and agency media planning platforms. The technology enables life sciences companies and marketers to build custom HCP audiences using natural-language prompts, combining real-world evidence with OptimizeRx's EHR network data. NLAB will be available for platform integration starting August 2026.GlobeNewswire Inc. · Jun 25, 2026

OptimizeRx Continues Expansion of the Company’s Point-Of-Care NetworkOptimizeRx Corp. announced four new partner agreements expanding its point-of-care network, increasing National Provider Identifier (NPI) reach by 37% through exclusive partnerships with e-prescribing platforms and health systems access partners.GlobeNewswire Inc. · Dec 17, 2025

OptimizeRx Corporation Confirms Receipt of Notice of Director NominationsOptimizeRx Corp. has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders.GlobeNewswire Inc. · Mar 11, 2025

Smith Micro Software, Inc. (SMSI) Reports Q2 Loss, Misses Revenue EstimatesSmith Micro Software, Inc. reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a loss of $0.35. The company's revenue of $5.14 million also missed estimates. The stock has lost about 62.9% since the beginning of the year.Zacks Investment Research · Aug 1, 2024

New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations• 84% of Patients Arrive at Doctor Visits Underinformed• Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies• OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma ClientGlobeNewswire Inc. · Jun 20, 2024

Expert Ratings For OptimizeRxOptimizeRx (NASDAQ:OPRX) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.6, with a high estimate of $17.00 and a low estimate of $13.00. This current average has increased by 12.31% from the previous average price target of $13.00. Breaking Down Analyst Ratings: A Detailed Examination The analysis of recent analyst actions sheds light on the perception of OptimizeRx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Grossman Stifel Maintains Buy $13.00 $13.00 Constantine Davides JMP Securities Maintains Market Outperform $15.00 - Constantine Davides JMP Securities Announces Market Outperform $15.00 - David Grossman Stifel Maintains Buy $13.00 $13.00 Sean Dodge RBC Capital Maintains Outperform $17.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', ...Full story available on Benzinga.comBenzinga · May 15, 2024

OptimizeRx Reports First Quarter 2024 Financial ResultsWALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period.GlobeNewswire Inc. · May 14, 2024

OPRXOptimizeRx Corporation Common Stock

OPRX

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any OPRX yet.

Related Tickers

Earnings

Volume

96.56K

Next Earnings

November 5th